



You're invited to the 25th INTERNATIONAL
Thyroid Cancer Survivors' Virtual Conference
September 16-18, 2022

Sponsored by ThyCa: Thyroid Cancer Survivors' Association, Inc.SM • www.thyca.org

Confirmed Speakers as of August 9, 2022
Meet and learn from these experts!

Sarimar N. Agosto Salgado, MD, is an oncologic endocrinologist at Moffitt Cancer Center in Tampa, Florida. Dr. Agosto Salgado's clinical interest centers on the management of thyroid nodules and all stages and types of thyroid cancer, including administration of systemic therapies for aggressive tumors. She is also interested in the management of hereditary endocrine neoplasia disorders, pituitary tumors, adrenal tumors, adrenocortical carcinoma and pheochromocytoma-paraganglioma tumors. Her research interest focuses on intermediate-high risk thyroid cancers in terms of management, surveillance protocols, targeted therapies and potential redifferentiation of tumors resistant to radioactive iodine.



Zubair W. Baloch, MD, PhD, is professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania in Philadelphia, Pennsylvania. He earned his medical degree from Liaquat Medical College in Jamshoro, Pakistan and his PhD from Hahnemann University in Philadelphia. Dr. Baloch's research expertise is in molecular and immunopathology of thyroid neoplasia and his clinical expertise is in endocrine pathology (cytology and histopathology).



Douglas W. Ball, MD, is an endocrinologist at Johns Hopkins Medicine in Baltimore, Maryland. Dr. Ball is an associate professor of medicine specializing in Thyroid Cancer, Medullary Thyroid Cancer, and Multiple Endocrine Neoplasia. His laboratory studies mechanisms underlying the neuroendocrine phenotype seen in some human cancers. Dr. Ball is active in developing new therapies for medullary thyroid cancer, and works in this translational research program in collaboration with other researchers and clinicians. Dr. Ball graduated from George Washington University Medical School and completed further training in Internal Medicine and in Endocrinology and Metabolism at the University of Pittsburgh and Johns Hopkins University. He is the author of numerous peer-reviewed medical journal articles and has been a speaker at previous ThyCa educational events. He is a ThyCa medical advisor.



Erik Blomain, MD, PhD, is a radiation oncologist at Stanford University in California. Dr. Blomain earned his undergraduate degrees at Cornell University majoring in both Biology and Classic Civilizations. He completed the MD/PhD Program and completed his medical internship at Thomas Jefferson University in Philadelphia. His focus is on translational cancer research as well as patient-centered care, advocacy, and survivorship for cancer patients.



Marcia S. Brose, MD, PhD, is chief of cancer services and co-director of community clinical research at The Sidney Kimmel Cancer Center Jefferson Health in Philadelphia, Pennsylvania. Brose is an internationally recognized expert in thyroid cancer, rare cancers, and personalized therapy. She also served as global co-PI on the pivotal multi-institutional phase III DECISION trial of sorafenib in locally advanced or metastatic thyroid cancer and the COSMIC 311 trial of cabozantinib for patients in the second line. She is involved in clinical trials of new treatments for patients with advanced thyroid cancer. Her clinical focus is familial cancer syndromes and cancer risk evaluation, Phase I/II clinical trials, and novel drug target discovery. Her research focuses on genomic characterization of cancers of the head and neck, thyroid, and lung; novel drug target discovery; and the use of genetic testing in the diagnosis, prognostication, and treatment of cancer. Dr. Brose received her bachelor's degree from Amherst College, her medical degree from Cornell University Medical College, and her Ph.D. from The Rockefeller University. Dr. Brose is a ThyCa medical advisor.



Monica Fawzy Bryant, Esq., is a cancer rights attorney at Triage Cancer Center in Chicago, Illinois. Ms. Bryant is the chief operating officer for Triage Cancer, a national, nonprofit organization that provides education and resources on cancer survivorship issues. Throughout her career, Ms. Bryant has provided hundreds of educational seminars, written articles, and blogs, and appeared on community television and radio shows discussing healthcare-related legal issues. Ms. Bryant is an adjunct law professor at John Marshall School of Law in Chicago, teaching a class on Cancer Rights. Ms. Bryant currently serves on the executive committee of the American Bar Association's Breast Cancer Task Force. She focuses on disability insurance; employment rights; estate planning and medical decision making; financial health, legislative advocacy; health insurance options; health insurance navigation; and health care reform.



Naifa L. Busaidy, MD is an endocrinologist and associate professor in the Department of Endocrine Neoplasia and Hormonal Disorders at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Busaidy, the director of the Thyroid Nodule Clinic, specializes in thyroid cancer and has authored numerous peer-reviewed research articles and book chapters. Dr. Busaidy is a recipient of a ThyCa thyroid cancer research grant and has spoken at many ThyCa conferences. She is a ThyCa medical advisor.



Maria E. Cabanillas, MD, is an oncologic endocrinologist, professor, and the faculty director at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is the faculty director of clinical research in the Department of Endocrine Neoplasia at MD Anderson. As a clinician and clinical researcher, Dr. Cabanillas treats both early and advanced thyroid cancers, including medullary, differentiated, and anaplastic. Her research focus is in advanced and aggressive thyroid cancer and molecular targeted therapies and immunotherapy. She is a principal investigator on several clinical trials for treating advanced disease and has been a member of and currently serves on the board of directors of the International Thyroid Oncology Group (ITOG). She is a ThyCa medical advisor.



Mark S. Chambers, DMD, MS is chief of the section of Oral Oncology and Maxillofacial Prosthodontics in the Department of Head and Neck Surgery at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is the vice chair of Research Compliance and Regulatory Affairs. His clinical research efforts include studying the effects of stimulants, antibiotics, and enhancing the body's immune system to manage dry mouth and injuries to the mouth caused by radiation and/or chemotherapy. Dr. Chambers earned his DMD and an MS in Biological Sciences at the University of Louisville in Kentucky. Dr. Chambers is a ThyCa medical advisor.



Kaniksha Desai, MD, ECNU, is an endocrinologist and clinical assistant professor of endocrinology at Stanford University in Palo Alto, California. She completed her endocrinology fellowship at the Mayo Clinic in Jacksonville, Florida, with an emphasis on the management of patients with thyroid cancer. Dr. Desai's clinical practice, located in the Endocrinology Clinic Hoover Pavilion, Palo Alto, California, focuses on the management of patients with thyroid diseases, including thyroid nodules and thyroid cancers, and the management of patients with pituitary disorders. She also maintains board certification in neck ultrasonography and internal medicine.



Carlos S. Duque, MD, is a head and neck surgeon at the Hospital Pablo Tobón Uribe and Clínica Las Américas in Medellín, Colombia. Dr. Duque does research in surgery. His group's most recent publications are titled "Chyle fistula in advanced and metastatic thyroid cancer" and "Associations between somatic mutations and clinical manifestations in South American Hispanic patients with papillary thyroid cancer." Dr. Duque has published a book for thyroid cancer patients and is finishing the English version. He has led sessions in both English and Spanish at past ThyCa conferences.



Rosella Elisei, MD, is an endocrinologist at University of Pisa in Pisa, Italy. Dr. Elisei is an Associate Professor of Endocrinology at the University of Pisa. She is an expert clinician mainly involved in the management of thyroid cancer patients. Dr. Elisei received numerous international awards: the Light of Life Foundation for the best thyroid cancer researcher of 2011, the 2018 European Thyroid Association award as distinguished scientist in Thyroid research field, the JCEM award for the best clinical paper 2006, 2012, 2015 and 2016. Dr. Elisei is the author of 220 papers published in peer-reviewed Journals, 55 manuscripts in proceedings of meetings and book chapters, as well as more than 300 abstracts for national and international meetings. She also serves as a reviewer for several peer-reviewed journals and holds memberships in several professional associations. She is PI of several clinical trials for new target therapy in advanced thyroid cancer.



Jessica Foft is a clinical research coordinator and licensed phlebotomist with 10+ years of clinical research experience at University of California San Francisco in San Francisco, California. She works in the Neuro-Oncology/Neuro-Epidemiology Adult Glioma Study and UCSF Airway Clinical Research Center SPIROMICS study. She will coordinate the adult and pediatric arms of the MTC/MEN2 registry at UCSF.

Aime T. Franco, PhD, is an assistant professor and investigator with the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia in Philadelphia, Pennsylvania. Dr. Franco directs the newly established Pediatric Thyroid Cancer Translational Research Laboratory. She earned her PhD in Cancer Biology from Vanderbilt University, Nashville, Tennessee and conducted her postdoctoral fellowship in genetics of thyroid cancer at Memorial Sloan Kettering Cancer Center, New York, New York. Her research interests include the molecular biology and genetics of thyroid cancer and improving quality of life and survivorship outcomes for thyroid cancer. Dr. Franco is a recipient of a ThyCa thyroid cancer research grant and has spoken at many ThyCa conferences.



Laura Fugazzola, MD, is an associate professor of endocrinology and the head of the Center of Excellence in the diagnosis and treatment of thyroid cancer at the Istituto Auxologico Italiano IRCCS, Milan, Italy. Dr. Fugazzola concentrated her clinical and translational studies on differentiated and medullary thyroid cancer, and on thyroid dyshormonogenesis. She is the associate editor of the *European Journal of Endocrinology* and the *Journal of Clinical Endocrinology & Metabolism*. She is also an investigator or principal investigator for phase 3 protocols on TKIs for advanced thyroid cancer. Dr. Fugazzola has been one of the coauthors of the Italian consensus on thyroid cancer published in 2018 and the coordinator of the group which produced the 2019 European Thyroid Association Guidelines on advanced thyroid cancer. She is also the leader of the European Thyroid Association Cancer Group (ETA-CG).



Sana Ghaznavi, MD, is an endocrinologist and neuroendocrine tumour team lead at Tom Baker Cancer Centre, Calgary, Alberta, Canada. Dr. Ghaznavi is an academic endocrinologist at the University of Calgary, Canada. She graduated from the University of Alberta medical school, completed internal medicine and endocrinology residency at the University of Calgary, and completed an interdisciplinary thyroid cancer fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. Her practice focuses on the management of thyroid cancer patients. Her research interests include active surveillance of papillary microcarcinomas, re-sensitization therapy for radioiodine refractory thyroid cancer, and personalization of thyroid hormone replacement therapy.



Elizabeth G. Grubbs, MD, is a surgeon and professor in the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas. She earned her medical degree at Duke University School of Medicine in Durham, North Carolina, followed by postgraduate training at Duke and at the University of Texas MD Anderson Cancer Center. She is author of numerous peer-reviewed original research articles, as well as book chapters. Dr. Grubbs is a recipient of a ThyCa thyroid cancer research grant and has spoken at many ThyCa conferences. Dr. Grubbs is a ThyCa medical advisor.



Avital Harari, MD, MSc, is an endocrine surgeon and associate professor in the Department of Surgery at the UCLA David Geffen School of Medicine, at the University of California Los Angeles in Los Angeles, California. Dr. Harari received her medical degree with distinction at Washington University School of Medicine in St. Louis, graduating in the top 10% of her medical school class. She trained in general surgery at Columbia University in New York City prior to completing her endocrine surgery fellowship at the University of California, San Francisco. Dr. Harari's clinical and research interests include the multidisciplinary management of benign and malignant tumors of the adrenal, thyroid, and parathyroid glands as well as the neuroendocrine pancreas. She is also interested in familial endocrine disorders (such as multiple endocrine neoplasia). She offers a wide range of unique services including retroperitoneal or transabdominal laparoscopic adrenalectomy, mini-incision thyroid and parathyroid surgery, central and modified neck dissection, and laparoscopic removal of pancreatic tumors.



Ana O. Hoff, MD, is an endocrinologist at the University of Sao Paulo Medical School, Sao Paulo, Brazil. Dr. Hoff graduated from the Universidade De Brasilia (Unb) Faculdade De Medicina. She is an associate physician at the Onco Star Clinic Full Member of D'Or Oncology doctor of the clinical staff of Hospital São Luiz Itaim – Rede D'Or. She is also head of the Endocrinology Service of the Cancer Institute of the State of São Paulo/faculty of medicine at the University of São Paulo. Dr. Hoff completed her residency in endocrinology and metabolism in the combined program of Baylor College of Medicine and University of Texas MD Anderson Cancer Center. She received her doctorate in endocrinology from the Federal University of São Paulo. Dr. Hoff's research focus has included the various types of thyroid cancer, multiple endocrine neoplasia, adrenal carcinoma, osteoporosis, and bone loss in cancer patients.



Mimi I. Hu, MD, is an endocrinologist and professor at the University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Hu has served on the faculty at MD Anderson Cancer Center since 2007. Her clinical expertise is in the evaluation and treatment of patients with papillary, follicular, and medullary thyroid cancers, hereditary endocrine neoplasia disorders, and metabolic bone and mineral disorders. She is the primary investigator and collaborator on multiple clinical trials evaluating various targeted therapies for advanced thyroid cancer. Dr. Hu has published articles and book chapters evaluating the management of medullary thyroid cancer, multiple endocrine neoplasia, bone health in cancer patients, endocrine complications of head and neck surgery, and paraneoplastic endocrine disorders. Dr. Hu is a ThyCa medical advisor.



Anupam Kotwal, MD, is an endocrinologist and assistant professor in the Division of Diabetes, Endocrinology & Metabolism at the University of Nebraska Medical Center in Omaha, Nebraska. Dr. Kotwal is a physician-scientist actively engaged in research, clinical care, and education in the field of benign and malignant endocrine disorders. He received endocrinology training at Mayo Clinic Rochester. His clinical focus is on endocrinopathies from cancer therapies, thyroid nodules, thyroid cancer, and adrenal cancer. Dr. Kotwal performs neck ultrasonography and biopsies of thyroid nodules and neck lymph nodes for diagnosis and follow-up of patients with thyroid cancer. In a fortuitous turn of events, he was recently diagnosed with thyroid cancer which has provided him with a different outlook toward caring and empathizing with his patients. Dr. Kotwal's research aims to identify immune biomarkers for thyroid cancer and to characterize immunotherapy-induced endocrinopathies.



Jennifer Kwak, MD, is a nuclear medicine physician at the University of Colorado Hospital in Aurora, Colorado. Dr. Kwak also serves as an Associate Professor of Radiology-Nuclear Medicine and the Nuclear Radiology Fellowship Program Director. She earned undergraduate degree from Dartmouth College, and her medical degree from Tufts University School of Medicine in Boston, MA.



Amanda LaGreca, MD, is an endocrinologist and assistant professor of medicine at the University of Colorado School of Medicine in Aurora, Colorado. She received her medical degree from University of Buenos Aires and completed her residency at Yale-New Haven Medical Center in Connecticut.



Jochen H. Lorch, MD, MSc, is a medical oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts. He is the director of the Thyroid Cancer Center, Clinical Trials leader, director of the Endocrine Cancer Treatment Center, and associate professor of medicine at Harvard Medical School. Dr. Lorch is board certified in hematology, internal medicine, and medical oncology. His clinical interests include head and neck oncology and thyroid cancer. Dr. Lorch is a ThyCa medical advisor.



Haggi Mazeh, MD, FACS, FISA, is an endocrine surgeon at Hadassah Medical Center in Jerusalem. He is chairman of the Israel Endocrine Surgery Society and the Chief-of-Surgery at the Department of Surgery, Hadassah Medical Center, Mount Scopus, Jerusalem, Israel. Prof. Mazeh completed his general surgery residency at Hadassah Medical Center and his endocrine surgery fellowship at the University of Wisconsin. He is currently leading a high-volume Endocrine Surgery service and performs numerous thyroid, parathyroid, adrenal, and neuroendocrine surgeries. Prof. Mazeh has multiple and significant scientific contributions in Endocrine Surgery. His research is presented at national and international conferences and is published at high impact factor journals.



David G. McFadden, MD, is an endocrinologist at UT Southwestern Medical Center in Dallas, Texas. Dr. McFadden is an assistant professor of internal medicine and biochemistry. His clinical interest is in the treatment of tumors arising from endocrine glands, including thyroid cancer. He is a member of the American Thyroid Association and the International Thyroid Oncology Group and has been awarded research grants from the National Institutes of Health, American Thyroid Association, the Disease Oriented Clinical Scholars (DOCS) program at UT Southwestern, and the Cancer Prevention and Research Institute of Texas (CPRIT). His current research focuses on using genetic engineering and chemical screens to discover new treatments for cancer.



Beverly McLaughlin, MA, is a patient navigator at the University of Colorado Hospital in Aurora, Colorado. Ms. McLaughlin is a member of the administrative staff in the Division of Endocrinology, Diabetes, and Metabolism.



Daniel Morganstein, MD, MA (Cantab), FRCP, PhD, is an endocrinologist at The Royal Marden, Chelsea, United Kingdom. Dr. Morganstein's research interests include immunotherapy for high-risk neuroblastoma, the use of immune checkpoint inhibitors in paediatric cancers, and the development of precision medicine approaches for paediatric solid tumours. Dr Morganstein is experienced in all aspects of diabetes and endocrinology with particular interests in endocrine tumours, including neuroendocrine tumours, adrenal tumours and paragangliomas and thyroid cancer, including medullary thyroid cancer. He also has a particular interest in the management of diabetes during cancer treatment, and the hormonal effects of cancer treatments.



Caroline Nguyen, MD, is an endocrinologist and an assistant professor of clinical medicine in the Division of Endocrinology, Diabetes, and Metabolism and the Department of Obstetrics and Gynecology at Keck Medical Center of USC in Los Angeles, California. Her clinical and research interests are related to the diagnosis and treatment of thyroid disease with a special focus on thyroid disorders in pregnancy including hyperthyroidism, hypothyroidism, subclinical thyroid disease, thyroid cancer, Hashimoto's, and postpartum thyroiditis. She has published articles in Thyroid, the Journal of Clinical Endocrinology and Metabolism, Clinical Obstetrics and Gynecology, and Clinical Diabetes and Endocrinology.



Eyal Robenshtok, MD, is an endocrinologist at Beilinson Hospital and Davidoff Cancer Center in Petah Tikva, Israel. He graduated from the Hadassah Medical School in Jerusalem with his MD degree and completed his training in internal medicine and endocrinology at the Rabin Medical Center. In 2012 he completed the thyroid cancer fellowship at Memorial Sloan-Kettering Cancer Center, New York. Dr. Robenshtok believes in compassionate, state of the art medical treatment, with shared decision making to achieve the best goals for each individual patient. His research focuses on individualized, risk stratified management of thyroid cancer, and his studies were published in leading scientific journals, including JCEM, Thyroid and more. He is an active member of these professional organizations: ATA, ETA, IES, EORTC and ITOG.



Bruce Robinson, MD, is an endocrinologist and professor at the University of Sydney, Sydney, Australia. He has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital, since 1989. He has been chairman Hoc Mai Foundation, a major program in medical and health education and exchange with Vietnam since 2001. In 2015 Dr. Robinson was appointed as chair of Australia's peak advisory and funding body for medical research, National Health and Medical Research Council. His research has focused on identifying genetic changes which either predispose or directly cause endocrine tumors, and among other highlights has been the formation of an international consortium of families from around the world to study medullary thyroid carcinoma and pheochromocytoma.



Jonathon O. Russell, MD, is a thyroid surgeon at Johns Hopkins Medicine in Baltimore, Maryland. Dr. Russell is the director of endoscopic and robotic thyroid and parathyroid surgery and an associate professor of otolaryngology, head and neck surgery. He earned his medical degree from Case Western Reserve University School of Medicine and completed his residency in Otolaryngology Head and Neck Surgery at the Cleveland Clinic. Dr. Russell specializes in scarless transoral thyroidectomy, radiofrequency ablation of thyroid nodules, and parathyroidectomy. Dr. Russell is also the director of the Johns Hopkins Multi-Disciplinary Thyroid Tumor Center.



Mabel Ryder, MD, is an endocrinologist at the Mayo Clinic in Rochester, Minnesota. She earned her medical degree from the University of Texas and completed her fellowship and residency at the University of Cincinnati College of Medicine. Dr. Ryder specializes in head and neck cancer and nuclear medicine therapy. She has contributed to many publications on thyroid cancer.



Anna Sawka, MD, PhD, is a clinician scientist and endocrinologist at Toronto General Hospital Research Institute in Toronto, Canada. Dr. Sawka was recently promoted to professor in the Division of Endocrinology, Department of Medicine at the University of Toronto. She holds a PhD in Health Research Methodology/Biostatistics and Epidemiology from McMaster University. Her research focus is primarily in thyroid cancer.



Bryn Silverman is a writer and producer for film/TV based in Louisville, Kentucky. She graduated from the USC School of Cinematic Arts, and is an Associate Programmer, Tribeca Film Festival.

Julie Ann Sosa, MD, MA, FACS, FSSO, is an endocrine and oncologic surgeon at the University of California, San Francisco in San Francisco, California. She is also Chair, Department of Surgery and Professor in the Departments of Surgery and Medicine. Her previous position was at Duke University Medical Center in Durham, North Carolina. She is a principal investigator or co-principal investigator of studies of new drug treatments for differentiated thyroid cancer (papillary/follicular), medullary thyroid cancer, and anaplastic thyroid cancer. Following undergraduate education at Princeton University, she received an MA in Human Sciences at the University of Oxford in the United Kingdom and her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She received postgraduate training at Johns Hopkins Hospital as well as John Radcliffe and Churchill Hospitals in Oxford, England. Dr. Sosa is a ThyCa medical advisor.



Susan Spinosa is a ThyCa Volunteer.

Christine Spitzweg, MD, is an endocrinologist at Medizinische Klinik und Poliklinik IV in Munich, Germany. Dr. Spitzweg is a professor of medicine at the Department of Internal Medicine II, Ludwigs-Maximilians-University (LMU) Munich Campus Grosshadern. She obtained her medical degree from the Munich Medical School, LMU Munich. Dr. Spitzweg is the chair of the thyroid center and the co-chair of the center for neuroendocrine tumors at the LMU Munich. Dr. Spitzweg has been involved in both clinical practice and research with a special interest in benign and malignant thyroid disease. She directs the research laboratory for Molecular Endocrinology investigating expression and regulation of the sodium iodide symporter (NIS) in and outside of the thyroid gland, the role of NIS as a novel reporter and therapy gene in the management of non-thyroidal and thyroidal cancer as well as regulation of mesenchymal stem cell tumor homing and differentiation by thyroid hormones.



Cord Sturgeon, MD, MS, is the chief of endocrine surgery at Northwestern University Feinberg School of Medicine in Chicago, Illinois. He also serves as a physician Director of Informatics for the NMHC system since 2015. He completed his residency at the University of Illinois Hospital, and his fellowship at the University of California San Francisco Medical Center. His academic focus was clinical outcomes for thyroid cancer, hyperparathyroidism, and adrenal tumors including pheochromocytoma and adrenal cancers. Dr. Sturgeon's clinical focus is the treatment of thyroid and parathyroid disease. He has a special interest in Multiple Endocrine Neoplasia.



Vivek Subbiah, MD, is a clinical trialist and physician investigator at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is an associate professor in the Investigational Cancer Therapeutics department. He is the Center Clinical Medical Director of the Clinical Center for Targeted Therapy, Cancer Medicine division. Dr. Subbiah has a unique training background as he is one of the few physicians in the nation/world to have training in oncology in both adults and children. He is board certified in both Internal Medicine and Pediatrics and has completed fellowships in both adult and pediatric oncology at MD Anderson. He is primarily involved in translational cancer research and the design and conduct of early-phase biomarker-driven clinical trials, with a specialist interest in anti-body drug conjugates, radio-pharmaceuticals, immunoconjugates and basket trials.



Vineeth K. Sukrithan, MD, is a medical oncologist and assistant professor in the Division of Medical Oncology at Ohio State University Comprehensive Cancer Center in Columbus, Ohio. Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer.



Valentina D. Tarasova, MD, is an endocrinologist at Moffitt Cancer Center in Tampa, Florida. Dr. Tarasova received her MD at Kubansky State Medical University. She completed an internal medicine residency at Yale New Haven Hospital, Yale School of Medicine, New Haven, CT and an endocrinology, diabetes and metabolism fellowship at the University of Omaha, NE. Most recently, Dr. Tarasova has completed a thyroid cancer fellowship at Memorial Sloan Kettering Cancer Center. Dr. Tarasova's clinical interests include thyroid neoplasm, particularly diagnosis, monitoring and treatment of thyroid carcinoma (from low risk to advanced progressive forms of thyroid cancer). Her research interests include the role of molecular markers in diagnosing and determining the prognosis of thyroid neoplasm, risk stratification of patients with thyroid cancer and developing tools to estimate the prognosis and determine the management of patients with thyroid cancer.



R. Michael Tuttle, MD, is an endocrinologist at Memorial Sloan-Kettering Cancer Center in New York, New York. Dr. Tuttle is also a professor of medicine at the Joan and Sanford I. Weill Medical College of Cornell University. Dr. Tuttle's research projects in radiation-induced thyroid cancer have taken him from Kwajalein Atoll in the Marshall Islands to the Hanford Nuclear power-plant in Washington State to regions in Russia that were exposed to fallout from the Chernobyl accident. He served on the American Thyroid Association committee that produced the current guidelines for the management of benign and malignant thyroid nodules. He also chaired the National Comprehensive Cancer Network Thyroid Cancer panel and served on the Endocrinologic and Metabolic Drugs advisory committee of the U.S. Food and Drug Administration. Dr. Tuttle is a ThyCa medical advisor.



Danica Vodopivec Kuri, MD, is an endocrinologist and assistant professor of medicine at The University of Alabama at Birmingham, Department of Endocrinology, Diabetes and Metabolism in Birmingham, Alabama. After obtaining her medical degree at Universidad de Guayaquil in Ecuador, she completed an Internal Medicine residency at Lahey Clinic/Tufts University in Burlington, MA. She did her Endocrinology fellowship at Boston Medical Center/Boston University School of Medicine in Boston, MA followed by an oncologic endocrinology specialty fellowship at The University of Texas MD Anderson Cancer Center, Houston, TX. Throughout her training years she has participated in clinical and bench research dedicated to parathyroid neoplasia, multiple endocrine neoplasia syndrome, and tyrosine kinase inhibitors resistance mechanisms in thyroid cancer. Her scholarly activities have resulted into several peer-reviewed articles, book chapters, and quality improvement projects dedicated to better serve the community of patients presenting with various types of endocrine neoplasia, in particular advanced thyroid cancer.



Jonathan Wadsley, MA, MRCP, FRCR, is an oncologist at Weston Park Hospital, in Sheffield, United Kingdom. He also serves as professor, Department of Oncology and Metabolism, University of Sheffield. His clinical interests are in thyroid cancer, neuroendocrine tumours and pancreatic/biliary tract cancers. He is a member of the Sheffield European Neuroendocrine Tumour Society Centre of Excellence team and provides clinical leadership for the Sheffield molecular radiotherapy service. Dr. Wadsley is the academic director for the directorate of Specialised Cancer Services and Clinical Director of the Sheffield Cancer Clinical Trials Centre. He has numerous national roles, including NIHR National Specialty Lead for Radiotherapy and Imaging, NIHR Cluster co-lead, chair of the NCRI Thyroid Cancer Group, and a member of ARSAC.



Steven G. Waguespack, MD, is an endocrinologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. A native of Louisiana, Dr. Waguespack graduated Summa Cum Laude from Loyola University in New Orleans, where he also participated in the presidential scholars' honor program. He graduated from the University of Texas-Houston Medical School with honors and pursued training in internal medicine/pediatrics at Indiana University Medical Center in Indianapolis. He completed a combined adult and pediatric endocrinology fellowship at Indiana University and is board certified in both subspecialties. Recognized as one of "America's Top Doctors for Cancer" in pediatric endocrinology, his major clinical and research interests are thyroid cancer, pituitary tumors, and metabolic bone disease. At MD Anderson Cancer Center, Dr. Waguespack provides endocrine care to patients of all ages. He is a ThyCa Medical Advisor.



Jonathan Wasserman, MD, PhD, is a pediatric endocrinologist and associate professor at The Hospital for Sick Children, Toronto, Ontario, Canada. He also serves as a project investigator of genetics and genome biology at the Research Institute. Dr. Wasserman's research focuses primarily on pediatric thyroid cancer and spans both clinical and translational domains. His research includes genetics and genomics of pediatric papillary thyroid cancer, health care utilization patterns among young patients with thyroid cancer at diagnosis and during follow-up and the identification of prediction models to improve assessment of thyroid nodules in children and to gauge malignant potential. He received his medical training at Harvard Medical School and the Massachusetts Institute of Technology and subsequently pursued an internship and residency in pediatrics at Children's Hospital in Boston. He previously earned a PhD and completed postdoctoral training in genetics at the University of Cambridge, England. Dr. Wasserman serves as co-chair of the American Thyroid Association's (ATA) Pediatric Thyroid Cancer Guidelines.



Mark E. Zafereo, MD, is a head and neck surgeon and associate professor at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is section chief of head and neck endocrine surgery and associate medical director of the Endocrine Center. He holds national committee appointments for professional associations and is past president of the Houston Society of Otolaryngology-Head and Neck Surgery. His clinical practice focuses on patients with thyroid cancer and parathyroid neoplasms. Dr. Zafereo is a ThyCa medical advisor.

